Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ripply transcriptional repressor 3 (RIPPLY3)
- Target
- RIPPLY3
- Molecular classification
- Transcription factor (corepressor)[1][2][3][6], Ripply family (InterPro IPR028127)[2]
01
Overview
Ripply transcriptional repressor 3 is a member of the Ripply family of transcriptional corepressors. It functions primarily as a negative regulator of transcription, and is essential for proper cardiac development via its repression of the cardiac transcription factor TBX1. Mutations or loss-of-function of RIPPLY3 are associated with conotruncal heart defects, suggesting a critical role in cardiac morphogenesis and embryonic development. RIPPLY3 is predicted to localize to the nucleus, where it mediates transcriptional repression by RNA polymerase II. While key in developmental biology, it is not an established or classical therapeutic target and there are no drugs known to act directly on this molecule[1][2][3][4][6][7].
- Other names
- DSCR6[1][3][4][6]ripply3 (symbol)[2]DSCR6_HUMAN (protein UniProt alias)[1]
02
Mechanism of action
Not applicable. RIPPLY3 acts by repressing TBX1 transcriptional activity through direct protein interactions; mechanisms of action for drugs are not documented[1][3].
03
Biological functions
Negative regulation of transcription by RNA polymerase II[1][2][3][4][7]Embryonic pattern specification[1][4][7]Negative regulation of cell population proliferation[1]Key negative regulator of TBX1-mediated cardiac gene activation (cardiac development)[1][3]
04
Disease associations
Conotruncal heart defects (loss-of-function mutations described as predisposing factors)[1][6]Potential role in cardiac morphogenesis and related congenital heart conditions[1][6]Cancer (gene expression perturbed in cancer datasets; role unclear in direct causation)[1]
05
Safety considerations
None described, as RIPPLY3 is not a current therapeutic target; however, genetic variants have been associated with congenital heart defect risk[1][6].
Beyond the preview
Go deeper on Ripply transcriptional repressor 3 (RIPPLY3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ripply transcriptional repressor 3 (RIPPLY3).